Orphazyme prepares for USD 50m capital hunt after nightmare year

After a year that brought Orphazyme failed studies and a rejection from the FDA, the Copenhagen-based biotech firm is now planning to bring in USD 50m by issuing American Depositary Shares (ADSs).

Photo: Orphazyme/PR

Biotech business Orphazyme, which is based in Copenhagen, Denmark, is planning to raise USD 50m through an American Depositary Shares (ADSs) issuance, it reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs